АШУҮИС — Судалгааны мэдээлэл (CRIS)
Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001
Browse
18 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association of Anthropometric Parameters and Severity of SARS-COV-2 Infection among Hospitalized Patients in a Tertiary care Center in Western Maharashtra – an Analytical Cross-Sectional Study(Mongolian National University of Medical Sciences, 2023-06-30) ;Shewte, Mamta Kishor ;Dhok, Rajeshree Sushil ;Pachange, Priyanka Narayanrao ;Suryawanshi`, Prachi ManoharSayed, Naila NazirBackground: On March 11, 2020, the World Health Organization (WHO) confirmed COVID-19 as a pandemic. COVID-19 has infected more than 5.5 million people worldwide, resulting in more than 3,47,000 fatalities. Obese individuals may be more susceptible to infection with SARSCoV-2. This study was conducted to assess the association between anthropometric parameters and the severity of SARS-CoV-2 infection. Methodology: This analytical cross-sectional study was undertaken on COVID-19-positive patients admitted to COVID-dedicated wards at a tertiary care center in Pune. The data was collected using a convenient sampling method from 185 COVID-19-positive patients. Result: Among those Positive for SARS-COV-2, 128 (69.19%) patients had mild COVID-19, and 57 (30.81%) patients were having severe COVID-19 disease. 36 patients (28.13%) with mild COVID-19 disease were average weight, 48 patients (37.50%) were overweight, and 42 patients (32.81%) were obese. Three (5.26%) of the 57 patients with severe COVID-19 disease were overweight, and 54 (94.74%) were obese. 19 (10.2%) patients had previously been diagnosed with hypertension, and 22 (11.8%) patients had both hypertension and diabetes. Conclusion: Obesity in patients with COVID-19 was associated with severe diseases, particularly pneumonia. Patients having underlying medical illnesses like hypertension and diabetes were found to be at higher risk of severe COVID-19. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, COVID-19 Surveillance in Nowshera District, Pakistan(Mongolian National University of Medical Sciences, 2020-06-25) ;Khan, Hamzullah ;Khalid, Muhammad ;Akhtar, MansoorHaris, MuhammadObjectives: To determine the frequency of 2019-nCoV infectivity and correlation of different variables with COVID-19 in the population of Nowshera District, Pakistan. Methods: In this prospective observational study, a total of 365 people suspected of having COVID-19 were included from February5, 2020, to April 25, 2020. Spearman's correlation was used to assess the correlation of various factors with COVID-19 test positivity. Results: The mean age and standard deviation of those assessed were 35 ± 16 years. Of the total, 264 (72.3%) were males and 101(27.7%) females. Of the 365 people suspected of having COVID-19, 148(40.54%) were selected for viral detection through PCR. Of 148, 41(27.70%) were COVID-19 positive. One hundred ninety-three (52.9%) of the participants had a history of contact with COVID-19 people suspected of having COVID-19, and 68 (18.6%) had a history of travel to an epidemic area with COVID-19. there was a positive correlation of PCR positivity of the participants with exposure (rs=0.23, p = 0.001) and travel history (rs = 0.12, p = 0.02), respectively. In gender groups, we observed a positive correlation of male gender with travel history (rs = 0.13, p = 0.02) and an increase in age (rs = 0.14, p = 0.006). Conclusions: The prevalence of infection was 27.70% using the PCR technique. Male gender and older age people were more at risk of developing COVID-19. There was a statistically significant correlation between viral infection and a history of travel to an epidemic area and close contact with COVID-19 patients. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Electrocardiographic and echocardiographic findings in long COVID-19: analyzing repolarization alterations and cardiac abnormalities(2024-12-17); ;Ch. Munkhsuren ;Batnaran Dagdan; Purpose.This study aims to identify and compare ECG and echocardiographic abnormalities in long COVID-19 patients, highlighting potential cardiac indicators. Material and methods.A hospital-based cross-sectional study with case-control analysis was conducted, we will add a detailed explanation of how patients were categorized into case (n = 60) and control groups (n = 60), based on specific criteria such as previously COVID-19 test, symptoms, ECG and echocardiographics with long COVID-19 related changes.Cardiac repolarization parameters, including TpTe interval and QTc interval, were evaluated through electrocardiography (ECG) (Nihon Kohden, 2016).Additionally, echocardiography (Xario 200, Canon, 2018) was employed to assess reactive pericarditis, cardiac contractility, and relaxation.Laboratory data were collected, and statistical analysis was performed using SPSS 26.0 software. Results.The study cohort had an average age of 45.7 ± 13.4 years.Among the findings, 35.7% of patients exhibited increased pericardial echogenicity, 23% had suspected reactive pericarditis, while 35.7% showed no elevated pericardial echogenicity.The Tp/Te interval, indicative of cardiac repolarization, was significantly prolonged in the case group (0.139 ± 0.02 sec) compared to the control group (0.089 ± 0.01 sec) (p < 0.001).Similarly, the QTc interval was extended by 0.559 ± 0.08 sec in the case group (QTc interval prolongation > 0.480 sec), demonstrating a significant difference from the control group (0.421 ± 0.03 sec) (p < 0.001).The linear regression analysis revealed significant associations between repolarization changes and several predictors in long COVID-19 patients.Notably, elevated triglycerides (β = 0.17, p < 0.001), cholesterol levels (β = 0.11, p < 0.001), TpTe (β = 2.09, p < 0.001), and reactive pericarditis (β = 0.05, p < 0.05) were identified as significant predictors of long COVID-19.Conclusion.Reactive pericarditis and repolarization changes, including TpTe and pericardial layer parameters, may manifest during the course of long COVID-19. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Knowing About Booster Shots Against COVID-19Since WHO designated Delta variant (B.1.617.2) as a variant of concern due to its high transmissibility, it has now been reported in more than 104 countries.Numerous research has shown that spread of the Delta variant is estimated to be 50-60% more contagious than Alpha variant which was first identified in the UK.The variant contains three RBD (receptor binding domain) mutations [1].-Lysine to asparagine substitution at amino acid position 417 in the S protein.This mutation is also common in Beta variant and involved in immune escape.-Leucine to arginine substitution at amino acid position 452 in the S protein.This mutation is common to the former variant of interest Epsilon and confers a stronger affinity to the ACE 2 receptor of various human cells.-Threonine to lysine substitution at amino acid position 478 in the S protein.This mutation is common in B.1.1.519variant predominantly present in Mexico.It has been predicted that change of the non-charged amino acid to positively charged amino acid may potentially switch the electrostatic surface of the protein which further increases ACE 2 binding affinity and immune evasion [2].Scientists reported that high transmissibility of the variant could come from the combination of its high viral load (1000 times higher than original COVID-19 variant) and short incubation period [3].Now there is a question of whether vaccines could protect us against the infection of Delta variant of COVID-19.A study published in the New England Journal of Medicine demonstrated the effectiveness of the BNT16b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines against the Delta variant.Effectiveness of the first dose of each vaccine was markedly lower among persons infected with the Delta variant (35.6% and 30.0%, respectively), while after the second dose, the effectiveness was increased to 88% and 67%, respectively [4].Even though these numbers may be dramatically higher, the duration and durability of the protective immunity through vaccination is far more in doubt.According to numerous studies, vaccine efficacy seems to be fading over the time [5].A study published in Nature by Pouwels et al. revealed that BNT16b2 (Pfizer-BioNTech) vaccine efficacy fell to 85% after 30 days and 78% after 90 days of vaccination.In the case of ChAdOx1 (AstraZeneca) vaccine, 69% effectiveness against a high viral load 14 days after the second dose fell to 61% by 90 days [1].So this means that Delta variant can cause breakthrough infections in already vaccinated individuals due to vaccine effectiveness dropping away over time.This is the main reason why Booster vaccination is important right now against currently circulating variants. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Persistent Post-COVID Syndrome (PPCS): Neurological Sequelae(Mongolian National University of Medical Sciences, 2022-04-01); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Relationship Between Coronavirus Infection and Liver Disease(Mongolian National University of Medical Sciences, 2020-09-25); ;Dorjgotov, Badamsuren - Some of the metrics are blocked by yourconsent settings
Item type:Publication, High Sodium Intake - A Cause of Low COVID-19 Severity Among Mongolians?(Mongolian National University of Medical Sciences, 2020-06-25); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The mortality burden related to COVID-19 in 2020 and 2021 - years of life lost and excess mortality in 13 countries and sub-national regions in Southern and Eastern Europe, and Central Asia(2024) ;Cawley, Caoimhe ;Barsbay, Mehtap Çakmak ;Djamangulova, Tolkun; Cilović-Lagarija, ŠeilaINTRODUCTION: Between 2021 and 2023, a project was funded in order to explore the mortality burden (YLL-Years of Life Lost, excess mortality) of COVID-19 in Southern and Eastern Europe, and Central Asia. METHODS: For each national or sub-national region, data on COVID-19 deaths and population data were collected for the period March 2020 to December 2021. Unstandardized and age-standardised YLL rates were calculated according to standard burden of disease methodology. In addition, all-cause mortality data for the period 2015-2019 were collected and used as a baseline to estimate excess mortality in each national or sub-national region in the years 2020 and 2021. RESULTS: On average, 15-30 years of life were lost per death in the various countries and regions. Generally, YLL rates per 100,000 were higher in countries and regions in Southern and Eastern Europe compared to Central Asia. However, there were differences in how countries and regions defined and counted COVID-19 deaths. In most countries and sub-national regions, YLL rates per 100,000 (both age-standardised and unstandardized) were higher in 2021 compared to 2020, and higher amongst men compared to women. Some countries showed high excess mortality rates, suggesting under-diagnosis or under-reporting of COVID-19 deaths, and/or relatively large numbers of deaths due to indirect effects of the pandemic. CONCLUSION: Our results suggest that the COVID-19 mortality burden was greater in many countries and regions in Southern and Eastern Europe compared to Central Asia. However, heterogeneity in the data (differences in the definitions and counting of COVID-19 deaths) may have influenced our results. Understanding possible reasons for the differences was difficult, as many factors are likely to play a role (e.g., differences in the extent of public health and social measures to control the spread of COVID-19, differences in testing strategies and/or vaccination rates). Future cross-country analyses should try to develop structured approaches in an attempt to understand the relative importance of such factors. Furthermore, in order to improve the robustness and comparability of burden of disease indicators, efforts should be made to harmonise case definitions and reporting for COVID-19 deaths across countries.Scopus© Citations 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial(2026-04); ;Cook, Kaitlyn A ;Khudyakov, Polyna; BACKGROUND: Data from randomized controlled trials of vitamin D3 supplementation in modifying the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are sparse. OBJECTIVES: We evaluated the effect of vitamin D3 supplementation on healthcare utilization and other clinical outcomes among adults with coronavirus disease 2019 (COVID-19) and their close contacts. METHODS: We conducted a parallel 2-group randomized controlled double-blinded trial targeting free-living adults in the United States and Mongolia. Index participants with newly diagnosed COVID-19 were cluster-randomized with up to one of their cohabiting contacts either to an oral vitamin D3 loading dose of 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk or to placebo. Participants completed weekly questionnaires on healthcare utilization, disease severity, and long COVID (index participants) or new SARS-CoV-2 infection (household contacts). The primary outcome was ≥1 healthcare visits (including hospitalization) or death within 4 wk among the index participants. RESULTS: Index participants (n = 1747) were a median of 38.0 y old (IQR: 31.1-47.0), 65.6% female/other sex, 4.2% Black non-Hispanic, 4.8% Hispanic/Latinx, 43.2% Asian, 44.3% non-Hispanic White, and 44.9% vitamin D deficient or insufficient (25-hydroxyvitamin D3 <20 ng/mL). Baseline characteristics for the household contacts (n = 277) were similar. The 4-wk cumulative incidence of healthcare utilization in index participants did not significantly differ between the vitamin D3 (n = 863) and placebo (n = 884) groups [cumulative incidences, 0.28 compared with 0.29; odds ratio (OR), 0.97; 95% confidence interval (CI): 0.75, 1.24]. Similar nonsignificant results were observed for the prespecified secondary treatment and prevention outcomes, though per-protocol analyses showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID at 8 wk (OR, 0.78; 95% CI: 0.59, 1.03). No safety concerns were identified. CONCLUSIONS: Among adults with newly diagnosed SARS-CoV-2 infections, vitamin D3 supplementation did not significantly change the 4-wk cumulative incidence of healthcare utilization or COVID-19-related outcomes compared with placebo. Promising results for long COVID warrant further study. This study was registered at clinicaltrials.gov as NCT04536298. First registered on 1 September, 2020.Scopus© Citations 2
